{"id":"NCT00395343","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Sitagliptin Added-on to Insulin Study (0431-051)","officialTitle":"A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK0431) to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy (Alone or In Combination With Metformin)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-12-11","primaryCompletion":"2008-10-13","completion":"2008-10-13","firstPosted":"2006-11-02","resultsPosted":"2009-10-23","lastUpdate":"2017-05-12"},"enrollment":641,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"sitagliptin phosphate","otherNames":["MK0431","Januviaâ„¢"]},{"type":"DRUG","name":"Comparator : placebo (unspecified)","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on insulin or insulin/metformin combination therapy.","primaryOutcome":{"measure":"Change From Baseline in A1C at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Sitagliptin 100 mg q.d.","deltaMin":-0.59,"sd":null},{"arm":"Placebo","deltaMin":-0.03,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20092585"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":322},"commonTop":["Any Metabolism and nutrition disorders","Hypoglycaemia"]}}